Dual antiplatelet therapy in patients at high bleeding risk: less is more-more or less
- PMID: 36514977
- DOI: 10.1093/eurheartj/ehac713
Dual antiplatelet therapy in patients at high bleeding risk: less is more-more or less
Conflict of interest statement
Conflict of interest: D.C. declares speaker or consultant honoraria from Amgen, Arena, Chiesi, Daiichi Sankyo, Sanofi Aventis, and Terumo, and Institutional fees from Medtronic. A.G. has no conflict of interest to declare.
Comment on
-
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.Eur Heart J. 2023 Mar 14;44(11):954-968. doi: 10.1093/eurheartj/ehac706. Eur Heart J. 2023. PMID: 36477292
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
